|Invion Limited -- Australia Stock|| |
AUD 0.019 0.001 5.00%
We currently do not have informatin regarding Tom Coogan. This executive tanure with Invion Limited is not currenlty determined.
Executive Since 2012
61 7 3295 0500 http://invion.com.au
The company has return on total asset (ROA)
of (12.35) %
which means that it has lost $12.35 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (73.51) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 1.26 M in total debt with debt to equity ratio (D/E) of 15.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Invion Limited has Current Ratio of 0.25 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Invion Limited, a clinical-stage drug development company, develops treatments for inflammatory diseases in Australia and the United States. Its drug candidates also comprise INV104, a leukotriene receptor antagonist that reduces inflammation, constriction of the airways, and build-up of mucus in the lungs. Invion Limited operates under Drugs - Generic classification in Australia and traded on Australian Securities Exchange exchange. It employs 1 people.Invion Limited (IVX) is traded on Australian Securities Exchange in Australia. It is located in 924 Gympie Road and employs 1 people.